F. Jänicke
Impact in
- Cancer Research top 0.05%
- Protease and Inhibitor Mechanisms
- Breast Cancer Treatment Studies
- Oncology top 0.2%
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
Papers in
-
- Protease and Inhibitor Mechanisms 46
- Breast Cancer Treatment Studies 32
- Oncology 75
- HER2/EGFR in Cancer Research 23
- Cancer Cells and Metastasis 16
- Cancer Treatment and Pharmacology 16
- Co-authors
- Manfred Schmitt (40 shared papers)H. Graeff (53 shared papers)Nadia Harbeck (31 shared papers)Christoph Thomssen (39 shared papers)Klaus Pantel (13 shared papers)Volkmar Müller (26 shared papers)Norbert Avril (11 shared papers)L. Pache (17 shared papers)
- Journals
- European Journal of Cancer (12 papers)Breast Cancer Research and Treatment (10 papers)British Journal of Cancer (10 papers)Journal of Clinical Oncology (10 papers)Journal of Cancer Research and Clinical Oncology (7 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
F. Jänicke
175 papers receiving 11.0k citations
F. Jänicke's Hit Papers
Peers
Comparison fields: 5 of 133
- Cancer Research 5.4k
- Oncology 4.4k
- Immunology and Allergy 968
- Hematology 927
- Radiology, Nuclear Medicine and Imaging 1.3k
Countries citing papers authored by F. Jänicke
This map shows the geographic impact of F. Jänicke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Jänicke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Jänicke more than expected).
Fields of papers citing papers by F. Jänicke
This network shows the impact of papers produced by F. Jänicke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Jänicke. The network helps show where F. Jänicke may publish in the future.
Co-authors
The 25 scholars most cited alongside F. Jänicke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 183 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System Hit paper breakdown → | 2007 | 1109 |
| 2 | Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial Hit paper breakdown → | 2001 | 789 |
| 3 | 2000 | 390 | |
| 4 | The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. | 2000 | 352 |
| 5 | Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. | 2001 | 340 |
| 6 | 1997 | 330 | |
| 7 | 2001 | 325 | |
| 8 | 2005 | 319 | |
| 9 | 1993 | 299 | |
| 10 | 2007 | 288 | |
| 11 | 1991 | 286 | |
| 12 | 2003 | 203 | |
| 13 | Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. | 1992 | 196 |
| 14 | 1996 | 188 | |
| 15 | 1994 | 185 | |
| 16 | Molecular signature associated with bone marrow micrometastasis in human breast cancer. | 2003 | 179 |
| 17 | Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. | 2005 | 170 |
| 18 | Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. | 2003 | 167 |
| 19 | 1996 | 155 | |
| 20 | 1990 | 154 |
About F. Jänicke
F. Jänicke is a scholar working on Cancer Research, Oncology, Molecular Biology, Genetics and Immunology and Allergy, having authored 183 papers that have together received 11.3k indexed citations. Recurring topics across this work include Protease and Inhibitor Mechanisms (46 papers), Breast Cancer Treatment Studies (32 papers), HER2/EGFR in Cancer Research (23 papers), Estrogen and related hormone effects (20 papers), Cell Adhesion Molecules Research (19 papers), Cancer Cells and Metastasis (16 papers), Cancer Treatment and Pharmacology (16 papers) and Ovarian cancer diagnosis and treatment (15 papers). The work is most often cited by research in Cancer Research (5.4k citations), Oncology (4.4k citations), Immunology and Allergy (968 citations), Hematology (927 citations) and Radiology, Nuclear Medicine and Imaging (1.3k citations). F. Jänicke has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Manfred Schmitt, H. Graeff, Nadia Harbeck, Christoph Thomssen, Klaus Pantel, Volkmar Müller, Norbert Avril, L. Pache, J. Dose and Sabine Riethdorf. Their work appears in journals such as European Journal of Cancer, Breast Cancer Research and Treatment, British Journal of Cancer, Journal of Clinical Oncology and Journal of Cancer Research and Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.